Margaret V Ragni

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. pmc Risk factors for inhibitor formation in haemophilia: a prevalent case-control study
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 15:1074-82. 2009
  2. pmc Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial
    Margaret V Ragni
    University of Pittsburgh Medical Center, Department of Medicine, Division Hematology Oncology, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
    Expert Rev Hematol 4:495-507. 2011
  3. doi request reprint Viral pathogens
    M V Ragni
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    Haemophilia 16:40-6. 2010
  4. pmc Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model
    Margaret V Ragni
    Medicine Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
    Exp Hematol 37:744-54. 2009
  5. pmc Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Haemost 109:248-54. 2013
  6. ncbi request reprint Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 4306, USA
    Liver Transpl 11:1425-30. 2005
  7. doi request reprint Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective
    Allyson M Pishko
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    Thromb Haemost 108:303-10. 2012
  8. ncbi request reprint Safety of the new generation recombinant factor concentrates
    Kimberly W Schlesinger
    Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, PA 15213 4306, USA
    Expert Opin Drug Saf 1:213-23. 2002
  9. pmc No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation
    Veronica H Flood
    Department of Pediatrics, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 121:3742-4. 2013
  10. ncbi request reprint Hemophilia gene transfer: comparison with conventional protein replacement therapy
    Margaret V Ragni
    Division Hematology, Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4606, USA
    Semin Thromb Hemost 30:239-47. 2004

Collaborators

Detail Information

Publications25

  1. pmc Risk factors for inhibitor formation in haemophilia: a prevalent case-control study
    M V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 4306, USA
    Haemophilia 15:1074-82. 2009
    ..The ideal time to initiate prophylaxis to reduce CNS bleeding and inhibitor formation will require prospective studies...
  2. pmc Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial
    Margaret V Ragni
    University of Pittsburgh Medical Center, Department of Medicine, Division Hematology Oncology, and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA
    Expert Rev Hematol 4:495-507. 2011
    ....
  3. doi request reprint Viral pathogens
    M V Ragni
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh Medical Center and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA 15213 4306, USA
    Haemophilia 16:40-6. 2010
    ..The purpose of this chapter is to provide an update on three clinically significant transfusion-transmitted viral pathogens...
  4. pmc Factor VIII-pulsed dendritic cells reduce anti-factor VIII antibody formation in the hemophilia A mouse model
    Margaret V Ragni
    Medicine Hematology Oncology, University of Pittsburgh Medicine Center, Pittsburgh, PA 15213 4306, USA
    Exp Hematol 37:744-54. 2009
    ..VIII-pulsed DCre, propagated from bone marrow in the presence of granulocyte-macrophage colony-stimulating factor and transforming growth factor-beta, in achieving F.VIII tolerance...
  5. pmc Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology and Vascular Medicine Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Haemost 109:248-54. 2013
    ..In summary, rhIL-11 increases VWF levels in two of four DDAVP-unresponsive or allergic VWD and F.VIII levels in four of five mild or moderate haemophilia A subjects, suggesting its potential use in treatment of these disorders...
  6. ncbi request reprint Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213 4306, USA
    Liver Transpl 11:1425-30. 2005
    ..05. In conclusion, pretransplant survival appears shorter in HIV-positive OLTX candidates and is unrelated to severity of liver or HIV disease. Further study is warranted to determine risk factors for poorer pretransplant outcomes...
  7. doi request reprint Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective
    Allyson M Pishko
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    Thromb Haemost 108:303-10. 2012
    ..In conclusion, prophylactic LMWH given to decrease cancer-related mortality, with no conventional indication, appears economically reasonable if its suggested mortality benefit is confirmed in future trials...
  8. ncbi request reprint Safety of the new generation recombinant factor concentrates
    Kimberly W Schlesinger
    Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, PA 15213 4306, USA
    Expert Opin Drug Saf 1:213-23. 2002
    ..Despite this, recombinant factors remain the most attractive treatment approach for haemophilia. Future improvement awaits the development of safe and effective gene transfer technology...
  9. pmc No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation
    Veronica H Flood
    Department of Pediatrics, Division of Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 121:3742-4. 2013
    ..These results suggest that the presence of the D1472H sequence variation is not associated with a significant increase in bleeding symptoms, even in type 1 VWD subjects...
  10. ncbi request reprint Hemophilia gene transfer: comparison with conventional protein replacement therapy
    Margaret V Ragni
    Division Hematology, Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4606, USA
    Semin Thromb Hemost 30:239-47. 2004
    ..This article reviews and compares the risks and benefits of standard protein-based therapy with those of gene transfer, and considers how gene transfer might fit into state-of-the-art management of hemophilia...
  11. ncbi request reprint Survival of human immunodeficiency virus-infected liver transplant recipients
    Margaret V Ragni
    Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 4306, USA
    J Infect Dis 188:1412-20. 2003
    ..Further prospective studies are warranted...
  12. ncbi request reprint Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis
    Kenneth J Smith
    Medicine Hematology Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 4306, USA
    Thromb Haemost 100:447-52. 2008
    ..In conclusion, screening, counselling and prophylactic AC during high-risk periods in female relatives of FVL carriers is an economically favourable strategy...
  13. pmc Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies
    Timothy C Nichols
    Department of Medicine, Francis Owen Blood Research Laboratory, University of North Carolina, Chapel Hill, NC 27516, USA
    Thrombosis 2010:461238. 2010
    ..The current status of porcine and canine VWD are also reviewed as well as their potential role in future studies of VWF-related disorders of hemostasis and thrombosis...
  14. ncbi request reprint AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
    Catherine S Manno
    Department of Pediatrics, University of Pennsylvania and The Children s Hospital of Philadelphia, PA, 19104, USA
    Blood 101:2963-72. 2003
    ....
  15. ncbi request reprint Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans
    Shawn L Fultz
    Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA
    Am J Med 116:420-3. 2004
  16. ncbi request reprint Pulmonary embolism and spiral computerized tomographic scans
    Margaret V Ragni
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 4306, USA
    Curr Opin Pulm Med 15:430-8. 2009
    ..The purpose of this review is to summarize the state-of-the-art of radiographic pulmonary embolism detection and consider future directions to reduce this significant public health problem...
  17. doi request reprint Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery
    Colleen M Culley
    Drug Use and Disease State Management DUDSM Program, Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center UPMC, Pittsburgh, PA 15213, USA
    Am J Health Syst Pharm 66:1554-9. 2009
    ..The clinical outcomes, safety, and use of resources associated with the administration of factor VIIa (recombinant) to nonhemophilic patients requiring neurosurgery were evaluated...
  18. ncbi request reprint Genetics of bleeding disorders in women
    Enrico M Novelli
    Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Semin Thromb Hemost 34:509-19. 2008
    ..The purpose of this article is to review the genetics of inherited bleeding disorders in women, focusing on bleeding manifestations, diagnostic methodologies, and management...
  19. pmc Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates
    Enrico M Novelli
    Division of Hematology Oncology, University of Pittsburgh Medical Center UPMC, Vascular Medicine Institute VMI, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Am J Hematol 87:326-30. 2012
    ..Our results suggest that TSP1 levels are associated with more VOE, hydroxyurea use and lower rates of hemolysis. High TSP1 concentrations may indicate higher risk of the viscosity/vaso-occlusion phenotype of SCD...
  20. pmc Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia
    Margaret V Ragni
    Division Hematology Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Thromb Haemost 106:641-5. 2011
    ..0-13.5). rhIL-11 was well tolerated with grade 1 or less fluid retention, flushing, conjunctival erythema, and local bruising. In summary, rhIL-11 reduces menorrhagia safely and warrants further study...
  21. doi request reprint Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia
    Robert Francis Sidonio
    Division of Pediatric Hematology Oncology, Children s Hospital of Pittsburgh University of Pittsburgh Medical Center, Pittsburgh, PA 15201, USA
    J Pediatr 157:456-60, 460.e1. 2010
    ..To construct a decision analysis model to evaluate the cost utility of von Willebrand disease (VWD) testing in adolescents with menorrhagia...
  22. ncbi request reprint Safe passage: a plea for safety in hemophilia gene therapy
    Margaret V Ragni
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, and Hemophilia Center of Western PA, Pittsburgh, Pennsylvania 15213 4306, USA
    Mol Ther 6:436-40. 2002
  23. pmc Pulmonary embolism incidence is increasing with use of spiral computed tomography
    Nicholas A DeMonaco
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Am J Med 121:611-7. 2008
    ..Pulmonary embolism causes significant morbidity in hospitalized patients, yet few studies have explored the impact of spiral computed tomography (CT) scanning on diagnosis and clinical outcome...
  24. doi request reprint Anticoagulation duration in heterozygous factor V Leiden: a decision analysis
    Anna K Donovan
    Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Thromb Res 132:724-8. 2013
    ..Among individuals heterozygous for the factor V Leiden mutation, while venous thromboembolism recurrence risk is greater, the risk for bleeding is recognized to be lower, suggesting longer duration anticoagulation could be considered...
  25. doi request reprint Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective
    Craig D Seaman
    Department of Medicine, Division Hematology Oncology, University of Pittsburgh, USA
    Thromb Res 132:647-51. 2013
    ..Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in the prevention of recurrent venous thromboembolism (VTE). Whether rivaroxaban is cost-effective in the prevention of recurrent VTE, however, is not known...